Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasus trial of degarelix versus GnRH agonist with radiotherapy in very high-risk localized or locally advanced prostate cancer
2024-513450-30-00Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2024
- Modality
- Small Molecules, Peptides
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of degarelix, goserelin, triptorelin and leuprolide in prostate adenocarcinoma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Proportion of patients with PSA nadir <0.1 ng/mL within 6 months after completion of radiotherapy. Started Aug 2024; status: completed.
02
Drugs
degarelixgoserelintriptorelinleuprolide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on 2024-513450-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513450-30-00.